- Page 1 and 2: hematology education the education
- Page 3: Copyright Information ©2009 by Eur
- Page 7 and 8: Acute lymphoblastic leukemia 1-7 Ge
- Page 9 and 10: C.G. Mullighan Department of Pathol
- Page 11 and 12: is required for normal B-lymphoid c
- Page 13 and 14: Given the tremendous insights gaine
- Page 15 and 16: 78. Mullighan CG, Radtke I, Zhang J
- Page 17 and 18: gene expression via chromatin modif
- Page 19 and 20: This has prompted the hypothesis th
- Page 21 and 22: S. Izraeli Sheba Medical Center and
- Page 23 and 24: e the presence of lineage specific
- Page 25 and 26: E. Gudgin B. Huntly Department of H
- Page 27 and 28: Figure 2. A proposed roadmap for LS
- Page 29 and 30: differentiation previously alluded
- Page 31 and 32: Nat Rev Cancer 2004;4:394-400. 64.
- Page 33 and 34: esent reliable and robust markers f
- Page 35 and 36: with NPM1 mutations. 26 Recently, s
- Page 37 and 38: 199;82:3556-9. 60. Diverio D, Rossi
- Page 39 and 40: such as lenalidomide are being inve
- Page 41 and 42: possible favourable impact from hig
- Page 43 and 44: leukemia: final results of AML-13,
- Page 45 and 46: leukemia and myelodysplastic syndro
- Page 47 and 48: suggests a role for macrophages in
- Page 49 and 50: studies in the future will undoubte
- Page 51 and 52: 56. Mannucci PM. How I treat patien
- Page 53 and 54: score may become part of an initial
- Page 55 and 56:
vide type 2A, 4 and correlates to a
- Page 57 and 58:
eply to a rebuttal. J Thromb Haemos
- Page 59 and 60:
leeding or surgery. For this infusi
- Page 61 and 62:
or invasive procedures. 16 Two retr
- Page 63 and 64:
U. Klein Institute for Cancer Genet
- Page 65 and 66:
known to be activated as a result o
- Page 67 and 68:
ulation either into a GC-response w
- Page 69 and 70:
R. Rosenquist Department of Genetic
- Page 71 and 72:
that expression of CD38 correlated
- Page 73 and 74:
arrays was also predictive of poor
- Page 75 and 76:
901. 41. Kröber A, Bloehdorn J, Ha
- Page 77 and 78:
are inferior to those with mutated
- Page 79 and 80:
23: 2971-9. 8. Tam CS, O’Brien S,
- Page 81 and 82:
originates in a hematopoietic stem
- Page 83 and 84:
Some evidence for this comes from s
- Page 85 and 86:
chronic myelogenous leukemia patien
- Page 87 and 88:
ple, substitutions at M244, L248, F
- Page 89 and 90:
ABL T315I mutation have been report
- Page 91 and 92:
H. Kantarjian J. Cortes Department
- Page 93 and 94:
Table 3. Characteristics of second
- Page 95 and 96:
nilotinib, where colony growth with
- Page 97 and 98:
F. Efficace 1 M.A. Sprangers 2 1 He
- Page 99 and 100:
patients with CLL showing better re
- Page 101 and 102:
Table 2. Minimum standard criteria
- Page 103 and 104:
40. Fayers P, Hays R. Assessing Qua
- Page 105 and 106:
Table 1. Definitions. Term Definiti
- Page 107 and 108:
lation groups. The role of a predic
- Page 109 and 110:
E. Estey Fred Hutchinson Cancer Res
- Page 111 and 112:
informative the prior, the more dat
- Page 113 and 114:
powered phase 3 trials.” Examinat
- Page 115 and 116:
50% of DLBCL targeting various prot
- Page 117 and 118:
the class III, and the breakpoints
- Page 119 and 120:
with poor outcome in sporadic Burki
- Page 121 and 122:
tory DLBCL. 23 Twelve of fifty-five
- Page 123 and 124:
Figure 3. B-cell-receptor signaling
- Page 125 and 126:
Cattoretti G et al. NF{kappa}B acti
- Page 127 and 128:
increasing toxicity. 4 Thus, combin
- Page 129 and 130:
vage therapies with minimal toxicit
- Page 131 and 132:
E. Dzierzak Erasmus Medical Center,
- Page 133 and 134:
associated stem cells contributes t
- Page 135 and 136:
et al. Comparative study of stromal
- Page 137 and 138:
their biologic property to eliminat
- Page 139 and 140:
HSC to mature cells, and a reduced
- Page 141 and 142:
K. Lapid T. Lapidot Department of I
- Page 143 and 144:
HSPCs from the BM reservoir in resp
- Page 145 and 146:
mented (reviewed in 90). The BM is
- Page 147 and 148:
57. Kollet O, Dar A, Shivtiel S, Ka
- Page 149 and 150:
somatic hypermutation targets vario
- Page 151 and 152:
19. Mauz-Korholz C, Gorde-Grosjean
- Page 153 and 154:
2.In advanced-stages, could an aggr
- Page 155 and 156:
Table 1. Prognostic meaning of FDG-
- Page 157 and 158:
patients with advanced Hodgkin Lymp
- Page 159 and 160:
D.A. Eichenauer A. Engert First Dep
- Page 161 and 162:
arms had initially achieved CR). FF
- Page 163 and 164:
G. Morgan K. Boyd Brookes Lawley Bu
- Page 165 and 166:
Classification of myeloma Progress
- Page 167 and 168:
translocations (t(4;14), t(14;16),
- Page 169 and 170:
N.C. Munshi Boston VA Healthcare Sy
- Page 171 and 172:
approved for the treatment of MM, a
- Page 173 and 174:
Tai YT et al. p38MAPK inhibition en
- Page 175 and 176:
Table 1. Post-induction and postran
- Page 177 and 178:
Table 4. Randomized trials on treat
- Page 179 and 180:
patients with multiple myeloma. Hae
- Page 181 and 182:
improvement when treated with these
- Page 183 and 184:
some and protein synthesis were dif
- Page 185 and 186:
S.D. Nimer Division of Hematologic
- Page 187 and 188:
trols the movement of cells from G2
- Page 189 and 190:
M. Cazzola L. Malcovati Department
- Page 191 and 192:
vivals and probabilities of leukemi
- Page 193 and 194:
Table 5. WPSS risk-adapted treatmen
- Page 195 and 196:
erythroid dysplasia in patients wit
- Page 197 and 198:
myeloid malignancies were detected,
- Page 199 and 200:
nani A, et al. Cytogenetic studies
- Page 201 and 202:
anemia and prior history of PV have
- Page 203 and 204:
improvement in the degree of anemia
- Page 205 and 206:
Table 2. Proposed approach to treat
- Page 207 and 208:
Blood 2002;99:2255-8. 62. Hessling
- Page 209 and 210:
Table 1. Published trials of interf
- Page 211 and 212:
een published, as shown in Tables 1
- Page 213 and 214:
The current development of JAK2 inh
- Page 215 and 216:
78. Gilbert HS. Long term treatment
- Page 217 and 218:
genetic abnormality in childhood MD
- Page 219 and 220:
Primary myelodysplastic syndrome wi
- Page 221 and 222:
ical care and elucidating the patho
- Page 223 and 224:
Current controversies in the treatm
- Page 225 and 226:
elapses in the donor group, but thi
- Page 227 and 228:
study. Despite such an internationa
- Page 229 and 230:
M.L. Randi M.C. Putti 1 Dept of Med
- Page 231 and 232:
nosis in agreement with Passamonti
- Page 233 and 234:
References 1. Adamson JW, Fialkow P
- Page 235 and 236:
N. Mohandas New York Blood Center,
- Page 237 and 238:
Table 1. Gene mutation in inherited
- Page 239 and 240:
normal surface area. The inheritanc
- Page 241 and 242:
M.H. Steinberg Department of Medici
- Page 243 and 244:
Priapism Priapism occurs in about 4
- Page 245 and 246:
16. Hoppe C, Klitz W, Noble J, Vigi
- Page 247 and 248:
Table 1. Causes of an absolute eryt
- Page 249 and 250:
een suggested. 24 In the congenital
- Page 251 and 252:
ine with relatively high doses of b
- Page 253 and 254:
immune recovery) 58 and disease rel
- Page 255 and 256:
References 1. Storb R. Allogeneic h
- Page 257 and 258:
geneic hematopoietic cell transplan
- Page 259 and 260:
isk and severity of acute and chron
- Page 261 and 262:
are simply delayed. The persistence
- Page 263 and 264:
Gualandi F, et al. Allogeneic bone
- Page 265 and 266:
Figure 1. Outcome of HSCT by donor
- Page 267 and 268:
RIC HSCT can be applied to patients
- Page 269 and 270:
P.H. Reitsma Einthoven Laboratory f
- Page 271 and 272:
seems to be associated with age-rel
- Page 273 and 274:
ia due to a previously unrecognized
- Page 275 and 276:
D-dimer test evaluations, and showe
- Page 277 and 278:
This is also the case, even in esse
- Page 279 and 280:
A. Kleinjan H.R. Büller Department
- Page 281 and 282:
Figure 1. The new anticoagulants an
- Page 283 and 284:
nant tissue factor pathway inhibito
- Page 285 and 286:
gens. 13,14 A study by Noumsi and M
- Page 287 and 288:
Table 1. Sickle cell hemolytic tran
- Page 289 and 290:
Intern Med 1980;93:231-4. 57. Culli
- Page 291 and 292:
may be extended to 7 days once ster
- Page 293 and 294:
have a full medical assessment and
- Page 295 and 296:
ethasone versus glycosylated G-CSF
- Page 297 and 298:
Table 1. Transfusion guidelines for
- Page 299 and 300:
Pretransfusion testing and product
- Page 301 and 302:
lood components from blood-related
- Page 303 and 304:
Precursor NK cell neoplasms NK cell
- Page 305 and 306:
Table 2. Clinical and biological fe
- Page 307 and 308:
ehavior between cytotoxic T and NK
- Page 309 and 310:
a single institute survey in Taiwan
- Page 311 and 312:
matosus, as well as in patients wit
- Page 313 and 314:
Figure 3. PCR for the TCRβ and TCR
- Page 315 and 316:
Wotherspoon A, et al. T-cell large
- Page 317 and 318:
antibody to Annexin A1, a very spec
- Page 319 and 320:
Table 2. Responses to rituximab in
- Page 321 and 322:
monoclonal antibody, in the treatme